| abstract |
FIELD: organic chemistry, chemical technology, medicine, pharmacy. n SUBSTANCE: invention relates to pharmaceutically acceptable salts of compound of the formula (I) n n n n or solvates of indicated salt wherein compound of the formula (I) is represented as (R)-enantiomer, (S)-enantiomer or racemate. Invention describes a pharmaceutically acceptable salt of compound of the formula (I) or solvate of indicated salt wherein compound of the formula (I) is represented as (R)-enantiomer, (S)-enantiomer or racemate under condition that (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-(2S,3S)-tartrate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-(2R,3R)-tartrate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide benzene sulfonate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-1,2-ethane disulfonate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide hydromaleate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide hydrosulfate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide D-gluconate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide hydrosuccinate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide methane sulfonate, (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamidehydro-(S)-maleate, (R)-N-[5-methyl-8-(4-methylpipearzine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide dihydrocitrate and (R)-N-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenamide hydrochloride are excluded. Also, invention describes a pharmaceutical composition based on salts and/or solvates by cl. 1-9 eliciting the selective effect on 5-hydroxytryptamine receptor subgroup, method for treatment based on using salts and/or solvates by cl. 1-9, and a method for preparing salt of solvate of compound of the formula (I). Invention provides preparing new salts and solvates of biologically active compounds. n EFFECT: improved preparing method, valuable medicinal properties of compound and composition. n 31 cl, 1 dwg, 18 ex |